Endometrial cancer starts in the tissue that lines your uterus. If the cancer is platinum-resistant, platinum-based chemotherapy drugs will not work well to kill it or stop it from returning after ...

Compared with chemotherapy alone, the addition of radiation to chemotherapy did not improve overall or recurrence-free survival in patients with locally advanced endometrial cancer, a new phase 3 ...

The first OnQ Prostate-assisted Focal One® Robotic HIFU procedure was successfully performed at UCSF, improving prostate cancer treatment precision. Cortechs.ai and EDAP TMS have announced the ...

The International Federation of Gynecology and Obstetrics (FIGO) staging systems for vulva, cervix, endometrium, and sarcomas have been revised for the first time in over a decade. The purpose of ...

By decoding how focal adhesions regulate lysosomal exocytosis, researchers are opening new doors to understanding cancer cell adhesion and migration and exploring innovative therapies targeting ...

San Diego, CA and Austin, Texas, February 6, 2025 - Cortechs.ai, an emerging leader in novel imaging solutions for prostate cancer care ... OnQ Prostate-assisted Focal One® Robotic HIFU procedure ...

Many cancers come with the risk of recurrence. That’s when the same type of cancer comes back after you have completed treatment and gone into remission. But some cancers, such as ovarian cancer ...

The 5-year relative survival rate for most cancers have improved in the last 40 years. The only exceptions are uterine (endometrial) cancer and cervical cancer—whose survival rates have declined.

China Endometrial cancer (EC) is the most common gynecological malignancy in developed countries, with rising incidence in recent years. Experimental animal models are crucial for studying the ...

EMB-09 is under clinical development by EpimAb Biotherapeutics and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I drugs for Endometrial Cancer have an 81% phase ...